期刊文献+

利培酮和氯氮平治疗儿童少年精神分裂症患者疗效与安全性比较 被引量:2

A Controlled Study of Clozapine and Risperide in the Treatment of Children with Schizophrenia
原文传递
导出
摘要 目的评价氯氮平和利培酮治疗儿童少年精神分裂症的疗效和安全性。方法145例儿童少年精神分裂症患者被随机分为氯氮平组(73例)和利培酮组(72例),住院治疗8周,用阳性与阴性症状量表(PANSS)和临床疗效总评量表(CGI)评定临床疗效,用副反应量表(TESS)评价安全性。结果在治疗4周和8周末,氯氮组患者阳性因子减分率均显著高于利培酮组(t=2.828,3.381,P<0.01),其它因子分及PANSS总分减分率两组患者比较均无显著差异(P>0.05);CGI疗效评定标准比较显示,氯氮平治疗效果优于利培酮(Ridit分析,μ=2.425,2.223,P<0.05)。利培酮治疗无效的患者换用氯氮平治疗后50%有效,氯氮平治疗无效的患者换用利培酮治疗后20%有效。氯氮平的不良反应主要有心动过速、心电图异常、白细胞下降、嗜睡、流涎、尿失控、头昏和癫痫发作,利培酮的不良反应主要有急性锥体外系反应和嗜睡;氯氮平组有9.6%的患者、利培酮组有2.8%的患者因不能耐受副反应退出治疗。结论氯氮平和利培酮均是有效的治疗儿童精神分裂症的药物,氯氮平的治疗效果、特别在改善阳性症状方面优于利培酮,但利培酮较氯氮平副作用少,安全性高。 Objective To evaluate the therapeutic and side effects of Clozapine and Risperide in the treatment of children with schizophrenia. Methods 145 patients with first episode childhood schizophrenia were assigned into Clozapine group (n=73) and Risperide group (n=72) by random allocation. The effects of treatment were evaluated with Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI). The side effects were evaluated with Treatment Emergent Symptom Scale (TESS). Results At the end of 4th and 8th week, decrease rate of scores for positive symptom was higher in Clozapine group then in Risperide group (t=2. 828, 3. 381, P〈0.01). By CGI assessment criterion, Clozapine was more effective than Risperide (Ridit analysis μ= 2. 425, 2. 223, P〈0.05). 50% of treatment-resistant patients to Risperide are effective by using Clozapine. 20% of treatment-resistant patients to clozapine are effective by using Risperide. The side effects of Clozapine include mainly tachycardia, abnormal cardiogram, white blood cell decreasing, hypersomnia, hypersalivation, urinary incontinence, faint and epileptic seizures. The side effects of Risperide include mainly extrapyramidal symtoms and hypersomnia. 9.6% of patients treated with Clozapine and 2.8 % with Risperide retreated from treatment because of the serious side effects result of medicine. Conclusion Both Clozapine and Risperide are effective in treating childhood schizophrenia. Clozapine is more effective than Risperide especially in treatment of positive symptom. But Risperide is less side effect and provides more safety than Clozapine.
出处 《中国健康心理学杂志》 2008年第3期311-314,共4页 China Journal of Health Psychology
关键词 儿童少年 精神分裂症 利培酮 氯氮平 Children Schizophrenia Risperide Clozapine
  • 相关文献

参考文献12

二级参考文献39

  • 1陈巧灵,黄劲松.利塔酮治疗64例少儿精神分裂症[J].上海精神医学,2003,15(1):30-32. 被引量:16
  • 2曾昭祥,李志成,刘琳,张昭才,王东坡,何秀俊,金卫东,王高华,刘仁刚.氯氮平与氯丙嗪对心电图影响的比较[J].临床精神医学杂志,1994,4(3):158-160. 被引量:14
  • 3张继志.新型抗精神病药利培酮[J].国外医学(精神病学分册),1995,22(3):137-139. 被引量:39
  • 4张明园.简明精神病量表(BPRS)[J].上海精神医学,1990,2:2-2.
  • 5[2]Heinrich K,Klieser E,Lehmann E et al.Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms.Prog Neuropsychopharmacol Biol Psychiatry,1994; 18:129
  • 6[5]Marder S R,Meibach R C.Risperidone in the treatment of schizophrenia.Am J Psychiary,1994,151:825~835
  • 7[6]Carman J,Peuskens J,Vangeneugden A.Risperidone in the treatment of negative symptoms of schizophrenia.International Clinical Psychopharmacology,1995,10(4):207~213
  • 8[7]Stip E,Lussier I.The effect of risperidone on cognition inpatient with schizophrenia.Canadian Journal of Psychiatry,1996,41(2):35~40
  • 9[1]Kopala LC, Fredrikson D, KP, et al. Symptoms in neurolepticnerve, first-episode schizophrenia: response to risperidone. Biol Psychiatry, 1998, 36: 296
  • 10[4]Lieberman JA, Mailman RB, Duncan G, et al. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry, 1998, 44: 1099~1117

共引文献72

同被引文献27

  • 1Jablensky A.Epidemiology of schizophrenia:The global burden of disease and disability[J].Eur Arch Psychiatry Clin Neurosci,2000,250(6):274-285.
  • 2Whiteford H A,Louisa D,Jurgen R,et al.Global burden of disease attributable to mental and substance use disorders:Findings from the Global Burden of Disease Study 2010.[J].Lancet,2013,382(9904):1575-1586.
  • 3Montgomery W,Liu L,Stensland M D,et al.The personal,societal,and economic burden of schizophrenia in the People's Republic of China:Implications for antipsychotic therapy[J].Clinicoecon Outcomes Res,2013,5(1):407-418.
  • 4Rapoport J L,Giedd J N,Gogtay N.Neurodevelopmental model of schizophrenia:Update 2012[J].Mol Psychiatry,2012,17(12):1228-1238.
  • 5Owen M J,O'Donovan M C,Thapar A,et al.Neurodevelopmental hypothesis of schizophrenia[J].British Journal of Psychiatry the Journal of Mental Science,2011,198(3):173-175.
  • 6Rapoport J L,Addington A M,Frangou S,et al.The neurodevelopmental model of schizop-hrenia:Update 2005[J].Mol Psychiatry,2005,10(5):434-449.
  • 7Chan R C K,Gottesman I I.Neurological soft signs as candidate endophenotypes for schizophrenia:A shooting star or a Northern star?[J].Neuroscience&Biobehavioral Reviews,2008,32(5):957-971.
  • 8Rossi A,De C S,Di M V,et al.Neurological soft signs in schizophrenia[J].British Journal of Psychiatry,1990,157(5):735-739.
  • 9Zabala A,Robles O,Parellada M,et al.Neurological soft signs in adolescents with first episode psychosis.[J].European Psychiatry the Journal of the Association of European Psychiatrists,2006,21(5):283-287.
  • 10American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders,text revision.4th ed.Washington,DC:American Psychiatric Association;2000.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部